Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07093775 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Additional Prognostic Value of Tumor Grade Beyond the 21-gene Recurrence Score

StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 30, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
To evaluated the prognostic significance of tumor grade in patients with node-negative, hormone receptor-positive, and human epidermal growth factor receptor 2-negative breast cancers treated according to RS-guided strategies.
Trial Details
NCT Number NCT07093775
Lead Sponsor Gangnam Severance Hospital
Conditions
(from sponsor)		 Breast Cancer, Tumor Grade
Related terms Breast Neoplasms
Enrollment 4,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov